Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study

Area of Science:

• Neuroscience
• Biotechnology
• Pharmacology

Background:

• The autophagy lysosomal pathway is vital for cellular health and is implicated in Parkinson's disease pathogenesis.
• Nanotechnology offers potential for delivering therapeutics to the central nervous system for neurodegenerative diseases.

Purpose of the Study:

• To develop a novel pharmaceutical technology for treating neurodegenerative diseases using a trehalose-based nanosystem.
• To enhance the delivery and efficacy of trehalose, an autophagy enhancer, for restoring impaired autophagy function.

Main Methods:

• Formulation of trehalose with an amphiphilic nucleolipid conjugate into solid lipid nanoparticles (SLNs) or poly(lactic-co-glycolic acid) (PLGA) nanoparticles.
• Characterization of nanoparticle size (SLNs: 120.4 ± 1.4 nm; PLGA: 167.2 ± 2.4 nm).
• In vitro biological assays to evaluate cellular uptake, safety, and autophagy induction.

Main Results:

• Successful formulation of trehalose-based nucleolipid nanoparticles with controlled size.
• Demonstrated safe and efficient cellular uptake of the nanoparticles in vitro.
• Confirmed induction of autophagy by the trehalose-loaded nanosystems.

Conclusions:

• Nucleolipid-based nanoparticles effectively deliver trehalose to cells, enhancing autophagy.
• This nanotechnology presents a promising therapeutic strategy for neurodegenerative diseases characterized by impaired autophagy.
• The developed nanosystem offers a potential tool to restore autophagy function in conditions like Parkinson's disease.